Myriad Genetics | MYGN - Current Assets


Myriad Genetics reported $312.8M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Agilent USD 4.76B 148M Mar/2026
Becton, Dickinson and Co. USD 8.01B 1.18B Mar/2026
Bio-Rad Laboratories USD 2.94B 35.9M Mar/2026
Bruker USD 2.1B 108.9M Mar/2026
Danaher USD 13.94B 1.18B Mar/2026
Illumina USD 2.74B 551M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Mettler Toledo International USD 1.33B 30.76M Mar/2026
Myriad Genetics USD 312.8M 19.8M Mar/2026
OraSure Technologies USD 240.78M 21.13M Mar/2026
Pacific Biosciences Of California USD 369.52M 5.54M Mar/2026
Quest Diagnostics USD 2.57B 188M Mar/2026
Quidel USD 1.38B 70.3M Mar/2026
Repligen USD 1.16B 23.98M Mar/2026
Revvity USD 2.13B 111.43M Mar/2026
Standard Biotools USD 521.45M 67.19M Mar/2026
Thermo Fisher Scientific USD 22.32B 6.39B Mar/2026
Veracyte USD 522.17M 33.8M Mar/2026
Waters USD 3.72B 1.73B Mar/2026